• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Crizanlizumab lowers pain crises in at-risk sickle cell patients, ad-hoc trial data show


Novartis’ investigational therapy for sickle cell disease (SCD), crizanlizumab (SEG101), was seen to reduce the number of patients reporting a pain crisis — including in those with a recent history of multiple crises — a post-hoc analysis of the SUSTAIN Phase 2 study reports.

More patients (35.8%) treated with crizanlizumab — among a study subgroup who had between two and 10 vaso-occlusive crises (VOCs) in the year prior to entering the trial — had no such crises post-treatment, compared to those given placebo (16.9%), its researchers reported. These findings were reported in the study, “Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis,” published in the American Journal of Hematology.

Crizanlizumab is a monoclonal antibody targeting P-selectin, a molecule existing on the surface of endothelial cells (which line the inner surface of blood vessels), and platelets (cell fragments involved in clotting).



To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.